Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 20, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-12-02-2015
- Volume 11
- Issue 12
Catalent Expands Biologics Capabilities
Author(s)Pharmaceutical Technology Editors
Expansions at Catalent’s Kansas City, MO, and Madison, WI facilities made in response to industry demand.
Advertisement
Catalent Pharma Solutions has announced the multi-site expansion of its analytical and process development capabilities for biologics including include an expansion of bioassay and protein characterization capabilities at its Kansas City, MO, facility, and additional integrated analytical capabilities at its Madison, WI, bio-manufacturing facility.
The investments were made in response to increased industry demand for large molecule analytical services, regulatory expectations around NBEs, and additional characterization requirements for biosimilars, the company reported in a Nov. 20, 2015 statement. The investment in Kansas City enables the facility to offer dual and complementary options for kinetic and quantitative binding assays for characterization and GMP testing.
The expansion at the Madison site will be operational by January 2016. The company has expanded process development capability at the Madison site, including integration of the Ambr 15 microbioreactor system into its cell line and upstream development.
Source:
Articles in this issue
almost 11 years ago
Software Corrects Spectra Dataalmost 11 years ago
Lab Reactor Designed for Scale-upalmost 11 years ago
Instrument Measures Endotoxins at Point of Usealmost 11 years ago
Instrument Manufacturers Collaborate on Interoperabilityalmost 11 years ago
HTS Reader Features Three Light Sourcesalmost 11 years ago
“A Hit for Every Target” and Changing the Model for Pharma Innovationalmost 11 years ago
Researchers Identify Advances for Heterocyclic Chemistryalmost 11 years ago
CMOs Lead Ongoing Drive for Single-Use Adoptionalmost 11 years ago
System Automates Traceabilityalmost 11 years ago
Lufthansa Cargo Offers CSafe ContainersAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5